Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), announces that it has been granted a patent in Japan. The intellectual property protection concentrates on the production of algal biomass, algal cell cultures, lipid compounds, and compositions thereof, including fatty acids, carotenoids, and fat-soluble vitamins. This patent adds additional strength to the Company's existing patent portfolio as it commercializes its line of organic Omega-3 products

According to the Principal Company survey "According to the survey, 35.1% of Japanese consumers "currently use" supplements. This is higher among women and the elderly population, with about 45% of women above 50 using supplements. The professional community in Asia is starting to take many of these products to help with weight management and nutritional deficiencies that come with their less active lifestyles."

"The marketplace is begging for nutritional supplements that meet the needs of these people. Companies like GNC and Nature Made are just starting to tap the Far East Asian market and bring products such as probiotics, multivitamins, DHA, and fish oil".*

After its initial product launch and further industry discussions, the Company has focused on supplying unique "clean label" products to satisfy the demand for premium plant-based, organic Omega-3 health products. In addition, the Company's wholly-owned subsidiary Eversea has accelerated efforts to offer organic marketing companies and organic-oriented retailers house-branded products (often termed "white label") based on our unique bioavailable Omega-3 ingredient. Channel marketing feedback indicates that there is extensive market demand for the product's unique characteristics, particularly among consumers focused on organic and vegan diets. The Company's patented Omega-3 active ingredient has obtained FDA NDI (New Dietary Ingredient) certification and is USDA and EU Organic Certified.

AboutSolarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The Company has successfully developed, patented, and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient. The Company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham, Chief Executive Officer

Phone: (647) 204-4095

Email: invest@solarvest.ca

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the terms of the Offering, the completion of the Offering, and the expected use of the net proceeds received by the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, level of activity, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; and regulatory risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement. The Company does not undertake to update any forward-looking information, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of Solarvest have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or " U.S. persons " (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation, or sale would be unlawful.

* Breaking into the Health Food and Supplement Market in Japan (principle-c.com)

Copyright (c) 2022 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

SVS:CA
The Conversation (0)
Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), is pleased to announce that its wholly-owned division Eversea America Inc. ("Eversea") has signed an agreement with E3Live, one of the organic industry's premier superfood brands. E3Live has agreed to introduce and market Eversea's organic omega-3 DHA products to its customer base

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest To Sell on China's E-Commerce Application Redbook

Solarvest To Sell on China's E-Commerce Application Redbook

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest ( TSXV:SVS ) is pleased to announce that the Eversea TM "branded" account has been launched on the Chinese e-commerce platform application Redbook

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Quarterly Financial Statements and MD&A

Solarvest Files Quarterly Financial Statements and MD&A

Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV: SVS) is pleased to announce that its quarterly statements for the period ended October 31, 2021, related management discussion and analysis have been filed and are now available on www.sedar.com.

For the three months ended October 31, 2021 the Company incurred a net loss of $383,510 compared to a net loss of $1,565,335 for the prior year. At October 31, 2021, the Company had $852,237 (July 31, 2021 - $1,388,244) in cash. Working capital at October 31, 2021 was $212,854 (July 31, 2021 - $587,732). Eversea had increased its inventory and inventory work in process over the last quarter to $29,289 finished goods and $199,156 work in process. This is an increase from the July 31 of $6,155 finished goods and $97,204 work in process.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Annual Financial Statements and MD&A

Solarvest Files Annual Financial Statements and MD&A

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - November 19 th 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS) is pleased to announce that its audited financial statements for the year ended July 31, 2021, related management discussion and analysis and associated officer's certifications (collectively, the "Annual Filings") have been filed and are now available on www.sedar.com .

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×